Opening book details…
Can I read Interleukin-2 Induced Immune Effects in Human Immunodeficiency Virus-infected Patients Receiving Intermittent Interleukin-2 Immunotherapy on EtoBox?
Interleukin-2 Induced Immune Effects in Human Immunodeficiency Virus-infected Patients Receiving Intermittent Interleukin-2 Immunotherapy by Joseph A. Kovacs; Susan Vogel; Julia A. Metcalf; Michael Baseler; Randy Stevens; Joseph Adelsberger; Richard Lempicki; Richard L. Hengel; Irini Sereti; Laurie Lambert; Robin L. Dewar; Richard T. Davey; Robert E. Walker; Judith Falloon; Michael A. Polis; Henry Masur; H. Clifford Lane is a Immunology and Microbiology article available to read on EtoBox.
What is Interleukin-2 Induced Immune Effects in Human Immunodeficiency Virus-infected Patients Receiving Intermittent Interleukin-2 Immunotherapy about?
To characterize the immunological effects of intermittent IL-2 therapy, which leads to selective increases in CD4 + T lymphocytes in HIV-infected patients, 11 patients underwent extensive immunological evaluation. While IL-2 induced changes in both CD4 + and CD8 + cell number acutely, only CD4 + cells showed sustained increases following discontinuation of IL-2. Transient increases in expression of the activation markers CD38 and HLA-DR were seen on both CD4 + and CD8 + cells, but CD25 ( § chain of the IL-2 receptor) increased exclusively on CD4 + cells. This increase in CD25 expression was sustained for months following discontinuation of IL-2, and was seen in naive as well as memory cells. IL-2 induced cell proliferation, but tachyphylaxis to these proliferative effects developed after 1 week despite continued IL-2 administration. It thus appears that sustained CD25 expression selectively on CD4 + cells is a critical component of the immunological response to IL-2, and that intermittent administration of IL-2 is necessary to overcome the tachyphylaxis to IL-2-induced proliferation.
Who reads Interleukin-2 Induced Immune Effects in Human Immunodeficiency Virus-infected Patients Receiving Intermittent Interleukin-2 Immunotherapy?
It is typically read by researchers, students, and practitioners in Immunology and Microbiology.
- Author
- Joseph A. Kovacs; Susan Vogel; Julia A. Metcalf; Michael Baseler; Randy Stevens; Joseph Adelsberger; Richard Lempicki; Richard L. Hengel; Irini Sereti; Laurie Lambert; Robin L. Dewar; Richard T. Davey; Robert E. Walker; Judith Falloon; Michael A. Polis; Henry Masur; H. Clifford Lane
- Publisher
- John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Ltd.; Wiley (ISSN 0014-2980)
- Published
- 2001
- Language
- EN
- Field
- Immunology and Microbiology (Life Sciences)